| Similar Articles |
|---|
 |
The Motley Fool
July 27, 2011
Michael Olsen |
Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment.   |
The Motley Fool
April 24, 2009
Robert Steyer |
Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services. |
The Motley Fool
August 9, 2006
Brian Gorman |
Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note. |
The Motley Fool
November 7, 2006
Brian Gorman |
Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
July 1, 2004
Brian Gorman |
Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
August 27, 2011
Michael Olsen |
Rising Star Buy: More Icon Icon shares might not appreciate tomorrow, and they might decline more before they go up. But here is a rare value: a secular growth story at a stellar valuation. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
May 4, 2005
Brian Gorman |
Relaxing on the River Charles River Laboratories' full suite of services looks like a winning concept. |
The Motley Fool
May 10, 2006
Brian Gorman |
Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now. |
The Motley Fool
February 9, 2006
Brian Gorman |
Charles River Bets on Preclinical The company is reportedly seeing more activity from biotech outfits, in addition to existing business from larger pharmaceutical names like Eli Lilly and Pfizer. But a large expansion in preclinical capacity warrants close watching. Investors, take note. |
AskMen.com
Dennis Ryan |
Winning The Triple Crown The Triple Crown of horse racing is almost impossible to win. |
Sports Central
June 19, 2010
Diane M. Grassi |
Horse Racing Industry Saddled With Financial Meltdown The 2010 thoroughbred horse racing season has seen its Triple Crown races pass, yet thoroughbred racing fans can still look ahead to some key summer races. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
